ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth quarter 2024 ...

Among the FDA’s pending decisions for this quarter are Vertex’s non-opioid pain drug and Sanofi’s RNA interference therapy ...

Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that CEO Neal Koller will present at the following investor conferences during J.P.

Vertex Pharmaceuticals Incorporated (NASDAQ ... These stocks are handpicked by our research director, Dr. Inan Dogan. • Ad-Free Browsing: Enjoy a year of investment research free from ...

Vertex Pharmaceuticals reported that its non-opioid drug reduced back pain significantly. But Vertex stock plunged as a placebo showed similar results. Moderna says it’s ‘one step closer’ to ...

Please watch the video at Investors.com - How To Sell Stocks: Long-Term Trend Lines Over 12 weeks, Vertex Pharmaceuticals ... Further, ad hoc analysis showed there was "variability in the placebo ...

Particular Audience, the global leader in AI-powered retail media technology, has been named in Forrester Research's 2025 NRF Innovators Report. This analysis spotlights 50 companies at the forefront ...

As we enter the new year, all eyes are on the biotech companies awaiting key FDA decisions in January. In 2024, the FDA approved 50 ...

Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.

Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an ...

Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...